4D Molecular Therapeutics (4DMT) Stock

4dmoleculartherapeutics.comHealthcareFounded: 2013Funding to Date: $109MM

4DMT is a biotechnology company focused on pioneering the development of precision gene therapies based on proprietary AAV vectors.

Register for Details

For more details on financing and valuation for 4D Molecular Therapeutics (4DMT), register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for 4D Molecular Therapeutics (4DMT).

Register Today

Team

Management Team

David Kirn MD
Chief Executive Officer, Chairman & Co-Founder
Melissa Kotterman Ph.D
Vice President, Discovery & Engineering & Co-Founder
August Moretti JD
Chief Financial Officer
Fred Kamal Ph.D
Chief Technology Officer
Peter Francis MD
Chief Medical Officer
Theresa Janke
Co-Founder & Chief Operating Officer
Leisa Johnson
Vice President, Pre-Clinical R&D, Pharmacology & Toxicology Program Leader, Lung Therapeutic Area
David Schaffer Ph.D
Co-Founder, Chief Scientific Advisor & Board Member

Board Members

Charles Theuer MD
Self
Deborah Marshall JD
Sidley Austin
Margi McLaughlin Ph.D
Self
David Schaeffer Ph.D
Hoyoung Huh Ph.D
Self
David Kirn MD
4DMT
Jacob Chacko MD
Self
Tony Yao Ph.D
ArrowMark Partners

Other companies like 4D Molecular Therapeutics (4DMT) in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
 
 
Sector
Last Round Est. Valuation
$1.08B